Bionorica

Bionorica is one of the world's leading manufacturers of herbal medicines. The company's interests lie in the production of products for the treatment of respiratory diseases, and drugs used in gynecology to reduce prolactin levels in women to combat cycle disorders and chest pain.

For more than 80 years, the company has been producing effective herbal medicines with a high level of proven effectiveness.

The company's equity ratio is 80%. Over the past 87 years, Bionorica has grown from a small private business to a global player with over 1800 employees. Most of the staff work in Germany (Neumarkt).

The company was founded in 1933 by Josef Popp, great-grandfather of the current owner, Professor Michael Popp. He sold the first natural medicines and about 400 different types of tea. The founder remained at the head of the company for twelve years until the company was taken over by his children in 1945: Erna Popp, a qualified pharmacist, and Dr. Hans-Oskar Popp, a physician specializing in natural medicines.

In 1961, Bionorica already has a filling machine and a labeling machine. At the same time, the first hired employees appeared.

During the 1970s and 80s. The company is growing steadily. Scientific research is becoming increasingly important.

Bionorica is one of the first pharmaceutical companies to start testing herbal medicines in double-blind controlled trials.

In 1989 Prof. Popp becomes CEO of Bionorica GmbH. The company sets global standards in the field of phytomedicine.

Bionorica creates two subsidiaries in Hungary: Herbekstrakt and Mediplant, which are engaged in the cultivation of plant materials for Bionorica.

In Mallorca, Bionorica Extracts S.L. begins its work, the main task of which is the cultivation of medicinal plants and the production of extracts.

1996 - Researchers at Bionorica discover a previously unknown property of sorrel as part of the anti-inflammatory action of Sinupret®. In addition, the antiviral effect of primrose and verbena has been proven.

1997 - Sinupret® and Sinupret® Forte are re-licensed in Germany. In the same year, Bionorica begins its own cultivation of thyme in Mallorca in order to obtain the optimum quality of raw materials for the production of Bronchipret®. The company standardizes production processes around the world.

2001 - Bionorica becomes a public company.

The company continues to grow and opens its representative office in Kiev (Ukraine) in 2000. The pharmaceutical manufacturer also buys Delta-9-Pharma GmbH.

2002 - The company introduces to the German market an active substance from hemp, which is of great importance for pharmacology.

In September 2003, Bionorica AG celebrated its 70th anniversary, which was attended by the Bavarian Prime Minister Dr. Edmund Stoiber.

2005 - The subsidiary "Bionorica Research GmbH" was founded in Innsbruck (Austria). His main areas of focus are research and development of herbal medicines, including in the field of respiratory diseases and chronic pain. This is the first private company of its kind in Austria.

In 2013 Bionorica celebrated its 80th anniversary. As part of this celebration, the company organized an international symposium "Phytoneering: one step ahead in thinking and research" in Berlin.

In 2019, Bionorica Group generated sales of 333.3 million euros, up 7.3% compared to the previous year (2018 - 310.7 million euros).